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Abstract 
Aging hypogonadal men are at increased risk of osteoporosis and sarcopenia. Testosterone is a 
potentially appealing strategy to prevent simultaneous bone and muscle loss. The androgen receptor 
(AR) mediates antiresorptive effects on trabecular bone via osteoblast-lineage cells, as well as 
muscle-anabolic actions. Sex steroids also modify the skeletal response to mechanical loading. 
However, it is unclear whether the effects of androgens on bone remain effective independent of 
mechanical stimulation or rather require indirect androgen effects via muscle. This study aims to 
characterize the effects and underlying mechanisms of androgens on disuse osteosarcopenia. Adult 
male mice received a unilateral botulinum toxin (BTx) injection, and underwent sham surgery or 
orchidectomy (ORX) without or with testosterone (ORX + T) or dihydrotestosterone (ORX + DHT) 
replacement. Compared to the contralateral internal control hindlimb, acute trabecular number and 
bone volume loss was increased by ORX and partially prevented DHT. T was more efficient and 
increased BV/TV in both hindlimbs over sham values, although it did not reduce the detrimental effect 
of BTx. Both androgens and BTx regulated trabecular osteoclast surface as well as tartrate-resistant 
acid phosphatase expression. Androgens also prevented BTx-induced body weight loss but did not 
significantly influence paralysis or muscle atrophy. BTx and ORX both reduced cortical thickness via 
endosteal expansion, which was prevented by T but not DHT. In long-term follow-up, the residual 
trabecular bone volume deficit in sham-BTx hindlimbs was prevented by DHT but T restored it more 
efficiently to pre-treatment levels. Conditional AR deletion in late osteoblasts and osteocytes or in the 
satellite cell lineage increased age-related trabecular bone loss in both hindlimbs without influencing 
the effect of BTx on trabecular osteopenia. We conclude that androgens have antiresorptive effects on 
trabecular disuse osteopenia which do not require AR actions on bone via muscle or via osteocytes. 
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1. Introduction 
Androgens are sex steroid hormones which act via the androgen receptor (AR) on bone and muscle 
cells [1, 2]. Testosterone (T), the principal circulating androgen, can activate AR directly or following 
conversion to dihydrotestosterone (DHT). T can also be aromatized into estrogens (whereas DHT 
cannot) to regulate male bone homeostasis, mainly via estrogen receptor α (ERα) [2, 3]. Over the last 
decade, the target cells of androgen actions on the musculoskeletal system have been investigated in 
AR knock-out (ARKO) mouse models using Cre/LoxP technology [4, 5]. These studies have shown 
that the antiresorptive effects of androgens on trabecular bone as seen in ubiquitous ARKO mice are 
recapitulated by conditional deletion of AR in the early osteoblast lineage, with some contribution from 
AR in late osteoblasts and osteocytes but not from AR in osteoclasts [3, 6-10]. The effects of T on 
endosteal resorption on the other hand are mediated via aromatization while the target cell(s) for 
androgen actions on periosteal bone formation remains elusive [2, 3, 11]. 
The anabolic effects of androgens on muscle are well known in humans [12, 13]. There is 
considerable interest in the use of T therapy in aging men, although this carries a risk of side-effects 
such as cardiovascular events, polycythemia and stimulation of prostate tissue. There is also growing 
realization that muscle may have indirect effects on bone via muscle-bone interactions [1, 14]. 
Because androgens like T have effects on both muscle and bone, they are theoretically an appealing 
strategy for the combination of disuse osteoporosis and sarcopenia [14, 15]. Furthermore, low serum T 
concentrations are often seen in situations of acute disuse [16-21]. However, whether muscle AR has 
direct effects on bone has not yet been reported. A better understanding of the target cells and 
underlying mechanisms of the beneficial effects of androgens is required to inform their appropriate 
use and to design alternative therapies which avoid their potential side-effects e.g. on the prostate and 
cardiovascular system [22, 23].  
Botulinum toxin (BTx) injection has been developed as an interesting preclinical model to study 
muscle-bone interactions [24-26]. By inhibiting specific proteins involved in vesicle fusion, BTx 
prevents presynaptic release of acetylcholine at the neuromuscular junction. Intramuscular injection of 
low BTx doses in rodents produces a local, transient (about 2-3 weeks) muscle paralysis with rapid 
trabecular bone resorption, followed by a partial recovery phase with residual unilateral 
osteosarcopenia [27-29]. The resultant cortical bone loss in contrast is more spatially heterogeneous 
[30-32]. Previous studies have suggested that androgens may have a beneficial effect on disuse 
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osteoporosis [16, 20, 33-36]. Importantly, sex steroids and their receptors are also known to influence 
mechanoresponsivity [14]. Androgens specifically have been reported to inhibit the osteogenic 
response to mechanical loading [37, 38]. Whether androgens also inhibit disuse osteoporosis via 
direct effects on bone or indirectly by preventing muscle atrophy remains unclear. We hypothesized 
that androgens would exert an anti-remodeling effect which would blunt the catabolic effects of disuse 
(which is beneficial), while at the same time they have been shown to reduce the osteogenic gains 
from mechanical loading (which is not a beneficial effect) [37, 38].  
Thus, the aim of this study was to investigate the target cells and mechanisms of AR actions in disuse 
osteoporosis. For this purpose, we performed unilateral hindlimb i.m. BTx injections in sham-operated 
or castrated mice given placebo, T or DHT replacement, or in mice with conditional deletion of the AR 
in late osteoblasts and osteocytes or in the satellite cell lineage. 
2. Materials and methods 
2.1.  Animals 
All mice were group-housed (3-5 animals/cage) in conventional animal facilities. Sixteen-week-old 
male C57BL6/J mice were purchased from Janvier Labs (Le Genest-Saint-Isle, France). Male mice 
heterozygous for a cyclization recombinase driven by the dentin matrix protein 1 promoter (Dmp1-Cre, 
a kind gift from dr. L. Bonewald, University of Missouri-Kansas City, Kansas City, MO-KS, USA) were 
bred with female mice homozygous for a floxed AR exon 2 allelle [39] to generate male AR
flox/Y
Cre
+/-
 
and AR
flox/Y
Cre
-/- 
control littermates as described [8]. Mice with conditional knock-out of AR in the 
satellite cell lineage were obtained by a similar breeding scheme using MyoD-iCre (generously 
donated by dr. D. Goldhamer, University of Connecticut, Storss, CT, USA) as reported [40, 41]. All 
mutant mice have been backcrossed onto a C57BL6/J genetic background and were genotyped as 
previously described [8, 40, 41]. The KU Leuven Ethical Committee for Animal Experimentation 
approved all procedures (P190/2011) and mice were treated in accordance with current Belgian 
national regulations for Animal Welfare and the 2010/63/EU directive. 
2.2. Experimental design and procedures 
Mice were operated under isoflurane anesthesia. At 16 weeks of age, mice received a unilateral 
hindlimb injection of botulinum toxin type A (Botox®, Allergan, Irvine, CA, USA) [24], 2 U/100 g body 
weight in 30 µL phosphate-buffered saline (PBS), divided over the quadriceps (15 µL), hamstrings (10 
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µL) and calf muscles (5 µL) [27] using a customized microsyringe (SGE Analytical Sciences, 
Bellefonte, PA, USA). Since the systemic effects of this treatment have been well characterized [25], 
we used the contralateral non-injected leg as an internal control. Muscle paralysis was quantified using 
the previously described digit abduction score [42] and the gait function inventory system [25]. The 
latter system involves a 0-2 point score on five items (total score range 0-10): (i) hindlimb abduction 
during tail suspension, (ii) toe extension during sitting, (iii) use of hindlimb during level walking, (iv) use 
of hindlimb during two legged stance, and (v) use of hindlimb during climbing [25] (Supplemental 
Video 1). Mice were provided energy-dense pellets and hydrogel on the bottom of the cage to 
facilitate eating and drinking during the first week post-injection. 
Mice were further divided into four experimental groups: sham surgery + placebo treatment (sham), 
orchidectomy + placebo (ORX), ORX + T or ORX + DHT. Sham surgery or ORX were performed via a 
suprapubic incision. Implants of medical-grade silicone tubing (Silclear, Degania Medical, Degania, 
Israel) sealed with medical adhesive silicone (Silastic, Biesterfeld, Germany) were implanted in the 
nuchal region, either empty (placebo) or filled with T (Serva, Heidelberg, Germany) or DHT (Sigma-
Aldrich, St. Louis, MO, USA), allowing continuous hormone release as described previously [38]. The 
resultant androgenic activity was assessed ex vivo by the wet weight of the androgen-sensitive 
seminal vesicles and levator ani/bulbocavernosus (LA/BC) muscle complex [41, 43]. 
To study the effects of androgens on acute disuse osteoporosis as well as during the recovery phase, 
hindlimb muscle and bone were imaged by in vivo microcomputed tomography (microCT) at baseline, 
after 3 weeks and at 4-weekly intervals thereafter for up to 7 or 19 weeks as indicated. Other mice 
were euthanized after 3 weeks for confirmation by dual-energy X-ray absorptiometry (DXA) and ex 
vivo microCT. A third group was euthanized after one week for gene expression analysis and 
histomorphometry (see below). 
2.3. DXA 
Bone mineral density (BMD), bone mineral content (BMC) and lean tissue mass were determined in 
the whole body (minus head) region and separately in the left and right hindlimb region of interest by 
in vivo DXA using the PIXImus mouse densitometer (Lunar Corp) with an ultrahigh resolution (0.18 × 
0.18 pixels, 1.6 line pairs/mm) and software v1.45. 
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2.4. MicroCT 
For in vivo microCT, both hindlimbs were scanned consecutively using a SkyScan 1076 (Bruker, 
Kontich, Belgium) [44] with the following settings: 9 µm pixel size, 1.0 mm Al filter, 50 kV, 100 µA, 1.0° 
rotation step, 180° angular rotation and 3300 ms integration time. The field of view included the distal 
two-thirds of the femur and the proximal two-thirds of the tibia, including the distal tibia-fibula junction. 
Ex vivo microCT was performed with a SkyScan 1172 microCT (Bruker, Kontich, Belgium) using 5 µm 
pixel size, 0.5 mm Al filter, 50 kV, 200 µA, 180° angular rotation at 0.6° steps, 590 ms integration time 
and averaging of two frames. All images were reconstructed using NRecon and analyzed by CTAn 
software as described [44]. For trabecular bone, a 1.5 mm region of interest in the proximal tibial 
metaphysis was selected, starting at 0.5 mm from the distal edge of the growth plate. For cortical 
bone, a 0.25 mm segment starting 0.5 mm proximally from the tibia-fibula junction was analyzed. 
Parameters included trabecular bone volume fraction (BV/TV, %), trabecular number (Tb.N, 1/mm), 
trabecular thickness (Tb.Th, mm), trabecular separation (Tb.Sp, mm), total cross-sectional tissue area 
(Tt.Ar, mm²), cortical bone area (Ct.Ar, mm²), medullary or marrow area (Ma.Ar, mm²) cortical 
thickness (Ct.Th, mm), periosteal perimeter (Ps.Pm, mm), endocortical perimeter (Ec.Pm, mm) and 
polar moment of inertia (J, mm
4
). For muscle area (in mm²), a single mid-calf slice at 5.0 mm from the 
distal edge of the proximal tibial growth plate was analyzed. 
2.5. Bone histomorphometry 
For bone histomorphometry, a group of mice was euthanized 3 weeks after BTx injection and surgery. 
These mice were injected i.p. with calcein (15 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) 4 and 1 
days before euthanasia. Bilateral tibias were fixed in Burkhardt's solution overnight, stored in ethanol 
for microCT analysis, embedded undecalcified in methylmethacrylate, and sectioned at 4 µm. Bilateral 
femurs were fixed overnight in PBS with 2% paraformaldehyde, stored in PBS, decalcified in 0.5 M 
ethylenediamine tetraacetic acid (EDTA) in PBS for 2 weeks at 4°C, followed by dehydratation in 
graded ethanol concentrations and embedding in paraffin. Paraffin sections (4 µm) were cut with a 
rotary microtome (Menzel-Gläser), dewaxed in xylene and rehydrated before staining. Osteoclasts 
were visualized with tartrate-resistant acid phosphatase (TRAcP) staining, and osteoclast surface per 
bone surface (%) was determined. The trabecular mineralizing surface to bone surface ratio (MS/BS) 
was calculated as the sum of the double-labeled surfaces (dLS) and the single-labeled surfaces 
divided by two ([dLS + 0.5*sLS] / BS). Since double labels were only evident in the ORX and not in 
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any of the other groups, the bone formation rate and mineral apposition rate could not be reliably 
assessed. All images were acquired and analyzed using a Zeiss Axiovert microscope with an 
Axiovision (v6.1.0) image analysis system using in-house software [38, 45, 46]. 
2.6. Quantitative PCR 
For gene expression analyses, mice were euthanized one week after BTx injection and surgery. 
Hindlimbs were immediately dissected, cleaned of soft tissue and snap-frozen in liquid nitrogen. Total 
RNA was extracted from crushed tibias using TRIzol reagent (Invitrogen), according to the 
manufacturer's protocols. After digestion with DNase I (Fermentas, St Leon-Rot, Germany), cDNA was 
synthesized from 1 μg RNA using the RevertAid M-MuLV Reverse Transcriptase kit (Fermentas) and 
random hexamer primers (Fermentas). The PCR reaction mixtures (10 μl) contained 1× Platinum 
SYBR Green qPCR SuperMix-UDG (Invitrogen), 0.15 μM of each primer, and 50 nM ROX reference 
dye (Invitrogen). The StepOne Plus Real-Time PCR system (Applied Biosystems, Foster City, CA, 
USA) was used. The primer sequences are listed in Supplemental Table S1. All primers were 
designed to hybridize to different exons, and generation of single amplicons was checked in melting 
curve assays. Gene expression was quantified using the absolute method with normalization to the 
levels of the housekeeping gene hypoxanthine guanine phosphoribosyl transferase (Hprt) [8]. 
2.7. Serum analyses 
Serum was obtained via cardiac puncture and bone turnover markers were assessed after 3 weeks of 
hormonal manipulation. Mouse serum TRAcP 5b was measured using an enzyme-linked 
immunosorbent assay from Immunodiagnostic systems (Paris, France) according to manufacturer 
instructions. Osteocalcin was measured using an in-house radioimmunoassay (RIA) as described 
previously [47]. 
2.8.  Statistical analysis 
Differences in continuous variables between sham, ORX, ORX+T and ORX+DHT groups were 
analyzed by one-way ANOVA followed by Bonferroni’s multiple comparisons test. For repeated 
measurements over time or to study the interaction effect between androgen groups and BTx 
treatment, two-way repeated measures ANOVA with Bonferroni post-test was used. Mean and 
standard error (SEM) are shown in all graphs unless specified otherwise. Analyses were performed 
using Graphpad Prism v5.04, and two-tailed P <0.05 was considered significant. 
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3. Results 
3.1. Effects of androgens on acute disuse osteoporosis 
As expected, BTx injection produced a transient muscle paralysis reflected by both an increase in the 
digit abduction score [42] (which recovered to baseline levels in approximately 2-3 weeks) and a 
decrease in the gait function inventory score [25], which recovered incompletely after 2-3 weeks (Fig. 
1A, B; P ≤ 0.0001 for change over time). This effect of BTx was not affected by androgens (nor was 
there significant interaction) (Fig. 1A, B). In line with previous reports that local BTx treatment 
produces systemic stress [25], all animals lost body weight, particularly in the first week after injection. 
This reduction in body weight loss was more pronounced following ORX and less pronounced in the 
ORX+T and ORX+DHT groups compared to sham (P ≤ 0.0001 for effect of BTx, androgens as well as 
interaction between treatments) (Fig. 1C). BTx induced atrophy of the quadriceps and calf muscles 
(gastrocnemius and soleus) (P ≤ 0.0001), which was not prevented by androgens (Fig. 1D, E). Also by 
DXA, lean tissue mass and BMC were decreased by BTx (P ≤ 0.0001) with no significant effect of or 
interaction with androgens (Fig. 1G, I). In contrast, BMD in the hindlimb regions of interest was 
decreased by both BTx (P ≤ 0.0001) and ORX (P=0.0005) (Fig. 1H). 
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Fig. 1. Acute intervention effects on disability, body and muscle weight. 
A) Evolution of the Digit abduction score and B) gait function score following BTx injection. C) Body weight loss 
(%) compared to each animal’s pre-treatment weight. Bonferroni post-test results are indicated as * = P < 0.05, ** 
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= P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. D) Quadriceps muscle weight, E) calf muscle weight, F) calf muscle 
area and G) limb lean mass by DXA after 3 weeks. H) Limb areal BMD and I) BMC by DXA. Asterisks indicate 
significant difference vs. internal control hindlimb in the same group (=BTx effect). Crosses indicate significant 
difference vs. same hindlimb in the sham group (=androgen effect). * = P < 0.05, **,
++
 = P ≤ 0.01, *** = ≤ 0.001,  
**** =  P ≤ 0.0001. N=7-9 animals per group in all panels. 
 
The dose of androgens was judged to be slightly supraphysiological based on the weights of the 
androgen-sensitive seminal vesicle and LA/BC muscles. In serum, both the bone resorption marker 
TRAcP 5b and the bone formation marker osteocalcin were increased by ORX and restored by T and 
DHT at the end of the 3 week intervention (Table 1). 
 
Table 1. Acute intervention effects on androgen status and bone turnover. 
 Sham ORX ORX+T ORX+DHT P value 
Seminal vesicle 
weight (g) 
0.2974 ± 
0.0120 
0.0496 ± 
0.0080*** 
0.4157 ± 
0.0130*** 
0.4612 ± 
0.0200*** 
≤ 0.0001 
LA/BC weight (g) 
0.0841 ± 
0.0025 
0.0420 ± 
0.0014*** 
0.0966 ± 
0.0044** 
0.0969 ± 
0.0057** 
≤ 0.0001 
BMD (g/cm²) 
0.0475 ± 
0.0005 
0.0454 ± 
0.0006* 
0.0468 ± 
0.0006 
0.0487 ± 
0.0003 
0.001 
TRAcP 5b (U/L) 5.27 ± 0.56 7.01 ± 0.36 ** 3.47 ± 0.42 * 3.85 ± 0.24 * < 0.0001 
Osteocalcin 
(ng/mL) 
38.0 ± 6.5 66.1 ± 6.0** 25.2 ± 3.1 21.2 ± 2.4 ≤ 0.0001 
Results are shown as mean ± SEM. N=7-9 for all outcomes. * = P <0.05, ** = P <0.01, *** = P <0.001 in 
Bonferroni post-test compared to sham. 
 
Trabecular bone volume at the end of the 3 week acute phase showed a significant effect of BTx, 
androgens as well as their interaction (all P ≤ 0.0001) (Fig. 2A). In the control limb, BV/TV loss was 
induced by ORX, prevented by DHT and even slightly above sham levels in the ORX+T group. BTx 
reduced BV/TV (P ≤ 0.0001 in all groups), however the difference attributable to BTx (in % compared 
to each animal’s internal control hindlimb) was greater in ORX and lower in the ORX+DHT group 
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compared to sham (Fig. 2B). Note that the difference in ORX+T was not significant in this analysis 
because of the higher BV/TV in the control leg. These differences were mainly due to changes in 
trabecular number (Fig. 2C), which also showed effects of androgens and BTx (both P ≤ 0.0001) as 
well as interaction (P=0.007). Again, the BTx-related difference was significantly lower in ORX+T and 
ORX+DHT than in ORX (Fig. 2D). Trabecular thickness (Tb.Th) was also affected by BTx (P ≤ 
0.0001), however less so by androgens (P=0.01). Still, the decrease in Tb.Th in the control hindlimb 
following ORX was prevented by T (but not DHT) (Fig. 2E). Trabecular separation on the other hand 
was mainly affected by ORX (P ≤ 0.0001) and less so by BTx (P=0.009), with no significant interaction 
(Fig. 2F). 
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Fig. 2. Effects of androgens on acute disuse osteoporosis. 
A) Trabecular bone volume in the proximal tibial metaphysis. B) BTx-related relative BV/TV difference (i.e. % 
difference compared to the internal control hindlimb in each animal). * = P <0.05, * = P <0.001 vs. sham. C) 
Trabecular number, D) BTx-related relative Tb.N difference. * = P < 0.05, *** = P < 0.001 vs. sham, 
+
 = P < 0.05 
vs. ORX.  E) Trabecular thickness, F) Trabecular separation. In graphs A, C, E and F, asterisks indicate 
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significant difference vs. internal control hindlimb in the same group (=BTx effect), whereas crosses indicate 
significant difference vs. same hindlimb in the sham group (=androgen effect). N=7-9 animals per group in all 
panels. G) Representative 3D models of trabecular region of interest (proximal 0.5 mm). 
 
Regarding cortical bone parameters, BTx reduced Ct.Th and Ct.Ar and increased Ma.Ar and Ec.Pm 
(Table 2). ORX also reduced Ct.Th and increased Ma.Ar. 
 
 
14 
 
Table 2. Cortical bone microCT parameters. 
 
Sham 
ctrl 
Sham 
BTx 
ORX 
ctrl 
ORX 
BTx 
T 
ctrl 
T 
BTx 
DHT 
ctrl 
DHT 
BTx 
P 
BTx 
P 
ORX 
Inter-
action 
Tt.Ar (mm²) 1.228 ± 0.030 1.215 ± 0.032 1.339 ± 0.081 1.278 ± 0.040 1.181 ± 0.093 1.144± 0.055 1.245 ± 0.022 1.243 ± 0.026 N.S. N.S. N.S. 
Ct.Ar (mm²) 0.778 ± 0.021 0.716 ± 0.016* 0.796 ± 0.055 0.702 ± 0.031** 0.780 ± 0.058 0.688 ± 0.027** 0.745 ± 0.011 0.694 ± 0.017* ≤ 0.0001 N.S. N.S. 
Ma.Ar (mm²) 0.451 ± 0.019 0.498 ± 0.021 0.543 ± 0.028 0.576 ± 0.023 0.401 ± 0.036 0.456 ± 0.036 0.500 ± 0.019 0.549 ± 0.020 0.0002 0.003 N.S. 
Ct.Th (mm) 0.131 ± 0.002 0.122 ± 0.002***  0.122 ± 0.002 
+
 0.115 ± 0.003* 0.133 ± 0.002 0.122 ± 0.003*** 0.126 ± 0.002 0.118 ± 0.002** ≤ 0.0001 0.007 N.S. 
Ps.Pm (mm) 4.284 ± 0.053 4.265 ± 0.059 4.534 ± 0.163 4.392 ± 0.082 4.219 ± 0.170 4.168 ± 0.112 4.331 ± 0.044 4.292 ± 0.048 N.S. N.S. N.S. 
Ec.Pm (mm) 2.864 ± 0.068 3.044 ± 0.078** 3.065 ± 0.110 3.210 ± 0.091 2.748 ± 0.156 2.856 ± 0.124 2.996 ± 0.072 3.136 ± 0.061 ≤ 0.0001 N.S. N.S. 
J (mm
4
) 0.214 ± 0.010 0.202 ± 0.009 0.247 ± 0.028 0.212 ± 0.013* 0.210 ± 0.036 0.184 ± 0.018 0.215 ± 0.007 0.204 ± 0.009 0.002 N.S. N.S. 
N=7-9 for all outcomes. Asterisks indicate significant difference vs. internal control hindlimb in the same group (=BTx effect). Cross indicates significant difference vs. same 
hindlimb in the sham group (=ORX effect on Ct.Th). *,
+
 = P <0.05, ** = P <0.01, *** = P <0.001 in Bonferroni post-test. N.S. = not significant. 
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TRAcP staining on trabecular bone at the end of the 3 week period revealed that average Oc.S/BS 
was significantly increased by ORX (P=0.0002) as well as by BTx (P=0.02), with the highest Oc.S/BS 
in the BTx hindlimb of the ORX group (Fig. 3A). The mineralizing surface (MS/BS) was increased by 
ORX and restored by T and DHT, with no significant effect of BTx (Fig. 3B). Representative 
microphotographs of the trabecular TRAcP staining are shown in Fig. 3C. To study the early changes 
in gene expression following BTx and androgen treatment, a separate group of mice was euthanized 
after one week. Results of qPCR analysis showed that both BTx (P=0.006) and ORX (P=0.02) 
increased Trap expression (Fig. 3E). A similar pattern was observed for Ctsk expression (BTx 
P=0.0005) although the effect of androgens was not significant (Fig. 3F). There was no significant 
effect of either treatment on Tnfrsf11a (Rank), Tnfsf11 (Rankl) or Tnfrsf11b (osteoprotegerin, Opg) 
expression, but the Rankl/Opg mRNA ratio was increased by BTx (P=0.001) (data not shown). There 
were no significant effects of either treatment after one week on Sp7, Tgfb1, Dmp1 or Sost expression 
(data not shown). 
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Fig. 3. Effects of androgens on osteoclast surface, mineralizing surface and gene expression in early 
disuse osteoporosis. 
A) Osteoclast surface by TRAcP staining on trabecular surfaces in the distal femoral metaphysis. B) Mineralizing 
surface by calcein labeling in the proximal tibial metaphysis. N=7-9 per condition in panels A-B. 
+
 = P < 0.05, 
++++
 
= P ≤ 0.0001 effect of androgens in Bonferroni post-test. C) Representative microphotographs of trabecular 
TRAcP staining in different conditions. D) Trap and E) Ctsk gene expression by qPCR. N=10 per condition in 
panels D-E. 
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3.2. Effects of androgens on recovery from acute disuse osteoporosis 
The long-term effects of androgens during the recovery phase were examined in a separate group of 
mice which also received BTx at 16 weeks of age. As judged by androgen-sensitive organ weights, 
ORX remained effective and the dose of T and DHT was again slightly supraphysiological (data not 
shown). The in vivo microCT results for trabecular bone are shown in Fig. 4A. After 7 weeks, BV/TV in 
both hindlimbs in the ORX groups was profoundly diminished such that meaningful quantification was 
no longer possible. At the end of this long-term study (week 19, age 26 weeks), there was a significant 
effect of both BTx (P ≤ 0.0001) and androgens (P=0.007) on BV/TV (Fig. 4B). Specifically, a 
significant difference remained at the end of the study period between the BTx and control hindlimbs 
in the sham group (P <0.01 by Bonferroni post-test). In the ORX+DHT group however, BV/TV in the 
BTx hindlimb was restored to sham-control levels, and the difference between the BTx and control 
limb was no longer significant in the ORX+DHT group. In the ORX+T group, BV/TV was restored to 
pre-treatment levels and increased above sham-control levels in both the BTx (P < 0.05) and control 
(P < 0.01) hindlimbs. 
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Fig. 4. Effects of androgens on recovery from acute disuse osteoporosis. 
A) Trabecular bone volume in the proximal tibial metaphysis. B) Results at the end of the 19 week study period. 
N=9 for sham and ORX groups, and N=5 for ORX+T and ORX+DHT groups. Asterisks indicate significant 
difference vs. internal control hindlimb in the same group (=BTx effect). Crosses indicate significant difference vs. 
same hindlimb in the sham group (=androgen effect). 
+
 = P < 0.05, **,
++
 = P < 0.01 in Bonferroni post-test. 
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3.3. Effects of conditional AR deletion using Dmp1-Cre and MyoD-Cre 
To investigate the possible target cells of the effects of androgens on disuse osteoporosis, we 
performed in vivo microCT in mice with conditional AR deletion in osteoblasts and osteocytes using 
Dmp1-Cre (ocyARKO mice) [8], and in the satellite cell lineage using MyoD-Cre (satARKO mice) [40]. 
We hypothesized that conditional ARKO might reproduce the effect of ORX and result in greater BTx-
related relative BV/TV difference compared to that of control mice. 
The results showed no difference in either the control or BTx leg between ocyARKO and controls at 0, 
3 or 7 weeks. At the 11 week time point (age 27 weeks), BV/TV loss became apparent in both the 
control and BTx limb of ocyARKO compared to controls, consistent with our previously reported 
phenotype at 32 weeks of age [8] (Fig. 5A). However the BTx-related difference (data not shown) was 
not increased in ocyARKO mice. 
In satARKO mice, there was no significant BV/TV difference after 0 or 3 weeks (data not shown). At 
the 7 week time point however, there was a significant effect of both BTx (P=0.0025) and satARKO (P 
= 0.016) with no significant interaction (Fig. 5B). Specifically, satARKO mice had lower BV/TV in both 
hindlimbs, but the BTx-related difference (data not shown) was not significantly different compared to 
control mice. 
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Fig. 5. Effects of conditional AR deletion using Dmp1-Cre (ocyARKO) or MyoD-Cre (satARKO) on acute 
disuse osteoporosis. 
A) Trabecular bone volume in the proximal tibial metaphysis by in vivo microCT in BTx and control hindlimbs of 
ocyARKO (N=7) and flox control mice (N=10), and B) satARKO (N=8) and control mice (N=13) after 7 weeks. 
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4. Discussion 
Androgens are an interesting candidate treatment for simultaneous bone loss and muscle atrophy as 
shown by previous preclinical studies on disuse osteosarcopenia [14, 16, 20, 33, 35, 36]. However, it 
is unclear whether the preventive actions of androgens on disuse osteoporosis are mediated via a 
direct effect on bone or merely result from indirect androgen effects on muscle. 
Our main findings are that both T and DHT mitigate BTx-induced trabecular bone resorption, in line 
with the known effects of AR on trabecular bone maintenance [3, 6-10]. This confirms findings in 
ARKO mice which have been reported to display greater hindlimb unloading-induced bone loss [48]. 
Orchidectomy increased not only bone resorption but also bone formation, as assessed by dynamic 
histomorphometry (Fig. 3B) and serum osteocalcin and TRAcP 5b concentrations (Table 1). This is 
expected since bone formation and resorption are coupled, and androgens are known to inhibit 
trabecular bone resorption by restraining bone turnover via an effect on osteoblasts [49, 50]. Thus, 
although androgens did not preserve trabecular bone via an effect on bone formation in our study, the 
effect of T may be different during growth since it was recently reported that disuse reduced trabecular 
bone formation which was restored by T at supraphysiological doses in young rats [20]. In both short-
term and long-term experiments however, we found that T was more effective than DHT in restoring 
trabecular bone volume. T also prevented BTx-induced endosteal expansion whereas DHT did not, 
suggesting that aromatization and estrogens are important for these effects of T. This is in line with the 
known effects of ERα on the trabecular and endosteal compartment in male mice [2, 3, 9, 51]. Thus, 
although pure androgens may exert some antiresorptive effects on the trabecular compartment, high-
dose T therapy may be more effective given the importance of aromatization for male skeletal health. 
Secondly, our data also clearly indicate that the prevention of disuse osteopenia by androgens did not 
require androgen effects on muscle. This was supported by the finding that androgens had no 
noticeable effects on BTx-induced paralysis or consequent limb lean mass, muscle weight or muscle 
area loss, although we cannot exclude a possible effect on other muscle properties or quality [40]. 
Other studies have likewise reported no effect of androgens on skeletal muscle loss in rodent acute 
disuse models, although this may depend on the timing of administration [14, 52, 53]. In mice, 
developmental AR deletion or ORX in young mice has significant but weak effects on appendicular 
muscle mass [40]. In adult mice however, we show that ORX without or with T or DHT replacement 
has no significant effect on appendicular muscle mass (and also not on grip strength, unpublished 
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data). Although androgens have an effect on both muscle mass and strength in humans, it is well 
known that anabolic effects are best achieved by combining androgens with resistance training [12, 
54]. In contrast, androgens at supraphysiological doses were able to prevent trabecular bone loss in 
our BTx study. Bone loss in this model is believed to result primarily from absence of muscle 
contractions [29]. Hence, our findings do not exclude the possibility that androgens might prevent 
acute disuse muscle atrophy in humans, but at least they support the conclusion that androgen effects 
on trabecular disuse osteopenia in mice are independent of the muscle anabolic actions of androgens. 
Furthermore, conditional deletion of AR in the satellite cell lineage [40, 41] was associated with 
accelerated age-related trabecular bone loss in both hindlimbs, similar to what we observed previously 
in ocyARKO mice [8]. This observation is novel and suggests indeed that developmental AR deletion 
in the satellite cell-lineage has not only direct effects on muscle but might also have secondary effects 
on bone, although further investigations are required to confirm these preliminary results [5]. 
Importantly however, the effect of BTx on trabecular bone was not increased in satARKO like in ORX, 
suggesting again that the effects of androgens on muscle are not a prerequisite for their prevention of 
disuse osteoporosis. 
Studies have shown that ERαKO mice (which have decreased bone turnover) have a diminished 
osteogenic response to mechanical loading [2, 55, 56] while ovariectomized, ARKO and ORX mice 
have increased bone turnover and display increased skeletal mechanoresponsivity [37, 38]. Thus, in 
combination with previous studies [37, 38, 48], it appears that androgens, via their anti-remodeling 
effect blunt both the detrimental skeletal effects of unloading as well as the bone-anabolic effects of 
mechanical stimulation. This is similar to what has been described for bisphosphonates (although 
androgens inhibit bone turnover by acting on osteoblasts rather than osteoclasts). The increased bone 
turnover and remodeling space following orchidectomy may determine the greater subsequent 
response (both positive and negative) to loading and unloading.  
Osteocytes are believed to play an important role in mechanosensitivity and skeletal adaptation to 
mechanical stimuli or disuse [14, 57]. However, neither osteocyte-specific ERαKO or ARKO male mice 
have an altered response to mechanical loading, suggesting that osteocytes are not the target cells of 
the effects of ERα and androgens [8, 58, 59]. Thus, it is not unexpected that ocyARKO also did not 
have greater trabecular bone loss following acute disuse like ORX mice did. The antiresorptive effects 
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of androgens are unlikely to be explained by AR in osteoclasts either [9, 10]. This leaves open several 
possible alternative target cells or mechanisms, the most likely of which is in our opinion a direct effect 
of androgens on osteoprogenitor cells or early osteoblasts [9]. Another interesting possibility in this 
regard was the systemic effect of androgens on body weight, since bone is well known to adapt to 
increasing bodily loads. Further studies using different conditional knock-out models e.g. 
osteoprogenitor cell-targeting Cre drivers [49], or different unloading techniques which allow correction 
for body weight [60] are required to investigate these possibilities. Another limitation of this study is 
that our Cre/LoxP knock-out models may not have completely abrogated AR expression and that 
compensatory effects may occur through other AR expressing cells e.g. muscle-resident fibroblasts [8, 
41]. Finally, we did not have non-irradiated controls in our long-term in vivo microCT studies, although 
our protocol produced a radiation dose of only 434 mGy which was previously validated to have no 
effect on trabecular microarchitecture per se after 3 sessions with a two week interval [45]. 
We conclude that androgens like DHT can prevent trabecular disuse osteopenia in adult male mice via 
an antiresorptive mechanism, while T has additional effects on BTx-induced trabecular and endosteal 
bone loss. AR in the satellite cell lineage or in osteocytes also regulates trabecular bone volume, but 
these mechanisms are dispensable for androgens to mitigate disuse osteoporosis. T therapy is an 
appealing candidate therapy which should be evaluated further in randomized clinical trials in 
hypogonadal men with disuse osteoporosis and/or sarcopenia. 
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